Fig. 1 · Structure

Documents & Downloads

Typhaneoside

Cat. No. A14478 CAS 104472-68-6
Typhaneoside is found in ginkgo nuts.

In Stock

Publications for Typhaneoside

1 publication citing this product

  1. Kuan-Ming Chiu, .et al. , Chem Res Toxicol, 2021, May 17;34(5):1286-1295 PMID: 33621091

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Typhaneoside Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Typhaneoside from 2 published references. In vitro models include free-fatty-acid-associated lipid accumulation in HepG2 cells.

Typhaneoside In Vitro Studies

Typhaneoside improved the MTT viability signal in challenged HUVECs at 0.56–70 μmol/L, while 0.11 μmol/L showed no detected benefit. At 70 μmol/L, it lowered MDA and NO-associated readouts and increased SOD activity. Separately, 50 μM typhaneoside reduced lipid accumulation readouts in HepG2 cells. These cellular results do not establish a direct molecular target. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Endothelial-cell viability and redox readouts

Cell-based study · Human umbilical vein endothelial cells (HUVECs), with normal-cell controls and LPS-associated injury [1]

Typhaneoside increased the MTT viability signal at 0.56–70 μmol/L relative to the injury control (reported p<0.01); 0.11 μmol/L had no detected benefit. Normal-cell viability remained >90% over 0.11–70 μmol/L. At 70 μmol/L, MDA and NO were lower and SOD activity higher than in the injury control. These assays do not establish a direct molecular target or distinguish increased proliferation from altered MTT metabolism.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MTT signal relative to untreated normal cellsrelative viability 58.35% in the injury control; improvement at 0.56–70 μmol/L (p<0.01); no effect at 0.11 μmol/L[1]
MDA at 70 μmol/L typhaneosideMDA concentration 1.91 ± 0.10 nmol/mL; p<0.05 versus injury control[1]
NO-associated nitrite readout at 70 μmol/L typhaneosideNO concentration 14.64 ± 0.08 μmol/L; p<0.01 versus injury control[1]
SOD activity at 70 μmol/L typhaneosideSOD activity 22.94 ± 2.48 U/mL; p<0.01 versus injury control[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.11, 0.56, 2.8, 14 and 70 μmol/L for viability; 2.8, 14 and 70 μmol/L for redox readouts
Exposure duration
MTT compound exposure: 24 h. Exact compound-versus-injury timing for all redox measurements is not clearly specified.
Method
Cell exposure; MTT and biochemical kit measurements
Vehicle
DMSO identified as solvent; final treatment percentage and explicit matched vehicle control are not stated.
Co-treatment
Injury stimulus used for challenged-cell comparisons; I3ON was a separate comparator, not a combination.
Reported limits
Sequence of compound and injury exposure is unclear. Figure n=5 is not explicitly defined as independent biological replicates. No direct target, target engagement or mechanistic rescue experiment.
Methods and source locations

Compound reported in the paper: Typhaneoside

Applies to the named research compound; does not validate an Adooq lot or transfer extract results to purified typhaneoside.

Materials and methods: Materials and reagents, MTT assay, Measurement of MDA/NO/SOD, Statistical analysis; Results and Figures 3–5

MTT signal relative to untreated normal cells: MTT; Figure 4 mean ± SD, n=5; independence of replicates unspecified — Results: Viability of LPS-induced HUVECs; Figure 4 and caption

MDA at 70 μmol/L typhaneoside: Thiobarbituric acid assay; mean ± SD, n=5 — Results: Measurement of MDA, NO and SOD; Figure 5 MDA panel/caption

NO-associated nitrite readout at 70 μmol/L typhaneoside: Griess nitrite assay; mean ± SD, n=5 — Results: Measurement of MDA, NO and SOD; Figure 5 NO panel/caption

SOD activity at 70 μmol/L typhaneoside: Xanthine/xanthine oxidase assay; mean ± SD, n=5 — Results: Measurement of MDA, NO and SOD; Figure 5 SOD panel/caption

Lipid accumulation in HepG2 cells

Cell-based study · Free-fatty-acid-associated lipid accumulation in HepG2 cells [2]

At 50 μM, parent TYP reduced cellular TG, TC and LDL-C readouts relative to the model group. Metabolites M3 and M5 produced larger TC and LDL-C effects than parent TYP according to Section 2.8. No numerical effect size or IC50 was extracted from the plots.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cellular triglyceride, total cholesterol and LDL-cholesteroldirection of change Lower than model group for parent TYP; no exact values extracted[2]

Literature-Reported Treatment Conditions

Treatment concentration
50 × 10−6 M (50 μM) TYP
Exposure duration
Free-fatty-acid modeling: 24 h; duration and sequence of TYP exposure not separately specified.
Method
HepG2 lipid accumulation model using 0.5 × 10−3 M free fatty acids (palmitic:oleic acid 1:2); parent and metabolite groups assessed separately.
Reported limits
Treatment vehicle, compound-exposure duration and cell replicate n are not specified in the reviewed method/caption; no exposure duration borrowed from the modeling step.
Methods and source locations

Compound reported in the paper: Typhaneoside; Compound label in the paper: TYP

Parent TYP dosing only; isolated metabolites and combinations are separate tested materials. Catalog SMILES omits stereochemical markers; lot stereochemistry is not established.

Section 2.8; Figure 8a–c and caption; Experimental Section Materials, HepG2 model and Statistical Analysis

Cellular triglyceride, total cholesterol and LDL-cholesterol: Commercial TG, TC and LDL-C kits; graphs use mmol/g protein — Section 2.8, first paragraph; Figure 8a–c; Experimental Section: The Lipid Accumulation Model of HepG2 Cells

Typhaneoside In Vivo Studies

In hyperlipidemic ob/ob mice, oral typhaneoside at 100 mg kg−1 d−1 for 21 d lowered plasma triglyceride and LDL-C readouts. The total-cholesterol and fasting-glucose comparisons are marked nonsignificant in Figure 8, despite broader significance claims in the Results narrative. Responses were attenuated in a microbiota-depleted treatment group; this alone does not establish the causal mechanism. [2]

Oral typhaneoside in hyperlipidemic ob/ob mice

Animal study · Leptin-deficient ob/ob mice; C57/6J normal controls as reported [2]

Oral parent TYP lowered plasma triglyceride and LDL-C readouts after 21 d. Figure 8 marks the parent-TYP TC and fasting-glucose comparisons nonsignificant; the Results narrative claims broader significance. The microbiota-depleted TYP group showed attenuated responses. Causal microbial attribution was not adopted because its additional controls and SI were outside the verified scope.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Plasma triglyceride and LDL-cholesterol after parent TYPdirection of change Lower than model group; mean ± SD shown, n=5 per group; no plot-derived decimals[2]
Total cholesterol and fasting blood glucose: parent TYP versus modelfigure significance annotation ns in Figure 8h,j; narrative describes significant reductions[2]

Conditions shared by the study groups

Route
Oral
Frequency
Daily total dose; number of administrations per day not separately specified.
Treatment course
21 d
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Parent typhaneoside in ob/ob mice
100 mg kg−1 d−1
Ob/ob model group (n=5); C57/6J mice as normal controls (n=5), as named by the authorsPlasma TG and LDL-C decreased relative to the model. Figure 8h,j annotate parent-TYP total-cholesterol and fasting-glucose comparisons as nonsignificant, despite broader significance wording in Section 2.8.[2]
Parent typhaneoside in ob/ob mice
Model: Ob/ob mice with hyperlipidemia; n=5 in TYP group
Reported limits: Sex, exact age, treatment vehicle, randomization and blinding not specified in the reviewed animal-design sections.
Methods and source locations

Compound reported in the paper: Typhaneoside; Compound label in the paper: TYP

Parent TYP dosing only; isolated metabolites and combinations are separate tested materials. Catalog SMILES omits stereochemical markers; lot stereochemistry is not established.

Section 2.8; Figure 8g–j; Experimental Section Animals, direct hyperlipidemia design and Statistical Analysis

Plasma triglyceride and LDL-cholesterol after parent TYP: Plasma lipid assays, Figure 8g,i; two-way ANOVA and Student t-test stated globally, exact test by panel unspecified — Section 2.8; Figure 8g,i; Experimental Section Statistical Analysis

Total cholesterol and fasting blood glucose: parent TYP versus model: Figure 8h,j, mean ± SD; n=5 per group in animal methods — Figure 8h,j compared with Section 2.8 paragraph beginning Next, in vivo experiments

Parent typhaneoside in ob/ob mice · Figure 8g–j; Section 2.8; Experimental Section: Animals and Effects of TYP, Bacterial Metabolites, and Butyrate on Hyperlipidemia In Vivo

Specifications

Manufacturer Adooq Bioscience
CAS Number 104472-68-6
Formula C34H42O20
Molecular Weight 770.68
SMILES
CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC(=C(C=C5)O)OC)OC6C(C(C(C(O6)C)O)O)O)O)O)O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 91 mg/mL (118.07 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Typhaneoside Research References

  1. [1] Peidong Chen, Yudan Cao, Beihua Bao, et al. Antioxidant capacity of Typha angustifolia extracts and two active flavonoids Pharmaceutical Biology (2017). PMID: 28274161 DOI: 10.1080/13880209.2017.1300818 Source material
  2. [2] Hui Xu, Ru Feng, Meng‐Liang Ye, et al. Multiple Enzymes Expressed by the Gut Microbiota Can Transform Typhaneoside and Are Associated with Improving Hyperlipidemia Advanced Science (2025). PMID: 39840606 DOI: 10.1002/advs.202411770 Source material

Publications

1 publication citing this product

  1. Kuan-Ming Chiu, .et al. , Chem Res Toxicol, 2021, May 17;34(5):1286-1295 PMID: 33621091

Added to your cart

View Cart Checkout
Loading...